Subject(s)

Biological Products/adverse effects , Coronavirus Infections/immunology , Interleukin-23 Subunit p19/antagonists & inhibitors , Pneumonia, Viral/immunology , Psoriasis/drug therapy , Respiratory Tract Infections/epidemiology , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Betacoronavirus/immunology , Biological Products/administration & dosage , COVID-19 , Clinical Decision-Making , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Coronavirus Infections/transmission , Humans , Interleukin-23 Subunit p19/metabolism , Odds Ratio , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/transmission , Psoriasis/immunology , Respiratory Tract Infections/chemically induced , Respiratory Tract Infections/immunology , Respiratory Tract Infections/prevention & control , Risk Assessment , SARS-CoV-2 , Signal Transduction/drug effects , Signal Transduction/immunology